Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991116 · ClinicalTrials.gov registry record · Phase 3
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 529
- Enrollment target
- 20
- Study locations
NCT04991116: Active Phase 3 study of Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
NCT04991116 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 529 participants, below the 842-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04991116, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 529 participants
- Enrollment target
- 20
- Study locations
Study Summary
An open label phase 3 study
Conditions Studied
Interventions
- DRUG TILD sub-cutaneous (SC) injection
Study Locations (20)
Florida
- Sunpharma site no 113 - Avon Park
- Sunpharma site no. 21 - Clearwater
- Sunpharma site no. 02 - Hialeah
- Sunpharma site no 71 - Kissimmee
- Sunpharma site no 107 - Margate
- Sunpharma site no. 05 - New Port Richey
- Sunpharma site no 32 - Ocoee
- SunPharma Site no 22 - Tamarac
California
- Sunpharma site no. 30 - Covina
- Sunpharma site no 110 - Encino
- Sunpharma site no. 17 - Fountain Valley
- Sunpharma site no. 15 - Thousand Oaks
Arizona
- Sunpharma site no 80 - Gilbert
- Sunpharma site no 65 - Mesa
- Sunpharma site no 105 - Phoenix
Illinois
- Sunpharma site no 51 - Orland Park
- Sunpharma site no 49 - Schaumburg
- Sunpharma site no 47 - Skokie
Alabama
- Sunpharma site no 50 - Dothan
Georgia
- Sunpharma site no 52 - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 529 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2029-04 |
| Phase | Phase 3 |
What the registry record for NCT04991116 still lists
NCT04991116 is an interventional study that assigns participants to a tested intervention. The registered 529 participants enrollment target is mid-sized for trials with a published cap, below the 842-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which TILD sub-cutaneous (SC) injection is the first listed.
NCT04991116 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04991116 about?
NCT04991116 is a clinical study titled "Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis". An open label phase 3 study
What is the current status of trial NCT04991116?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 529 participants. The study started on 2022-06-30. Estimated completion is 2029-04.
What conditions does trial NCT04991116 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT04991116?
The interventions under investigation include: TILD sub-cutaneous (SC) injection (DRUG).
Who is sponsoring clinical trial NCT04991116?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04991116 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04991116's enrollment target sits among peer trials
529 15th of 48 higher than 34 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI